# Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma

> **NCT00903175** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 471 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** everolimus
- **DRUG:** sunitinib

## Key facts

- **NCT ID:** NCT00903175
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 471 (ACTUAL)
- **Last updated:** 2016-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00903175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00903175, "Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00903175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*